Critical reviews in oncology/hematology最新文献

{"title":"Super enhancers as drivers of hallmarks of cancer: From oncogene activation to metastatic progression","authors":"Shuang Fan ,&nbsp;Yihang Gao ,&nbsp;Xinyu Dai ,&nbsp;Hui Ma ,&nbsp;Zecheng Yang","doi":"10.1016/j.critrevonc.2025.104826","DOIUrl":"10.1016/j.critrevonc.2025.104826","url":null,"abstract":"<div><div>Super enhancers (SEs) are a special type of enhancer with a unique shape and mechanism that allows them to regulate cellular processes by exhibiting a more significant gene transcription regulatory role than conventional enhancers. Tumorigenesis and metastasis may result from cancer cells exploiting SEs and developing a transcriptional addiction to them. Furthermore, tumor development may result from the translocation, creation, deletion, or duplication of SEs. According to reports, SEs closely control several carcinogenic chemicals and pathways. SE-targeting inhibitors can inhibit oncogene transcription and work in concert with chemotherapeutic drugs to overcome treatment resistance. In this work, we reviewed that SEs are essential players in the development of tumors, including the activation of oncogenes, the induction of tumor angiogenesis, the activation of invasion and metastasis, the control of immune checkpoint genes, cancer immune escape, cancer stem cells, and resistance to treatment. Additionally, we examined the therapeutic strategy and significant SE inhibitors that are helpful in cancer therapy in this research. The limits of SEs in malignancies, both present and prospective, have been covered last.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"214 ","pages":"Article 104826"},"PeriodicalIF":5.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual-target CAR-T cell therapy: A new strategy to improve the therapeutic effect of hematological malignancies","authors":"Shenyu Wang,&nbsp;Xin Li,&nbsp;Hongmei Ning,&nbsp;Yamei Wu","doi":"10.1016/j.critrevonc.2025.104824","DOIUrl":"10.1016/j.critrevonc.2025.104824","url":null,"abstract":"<div><div>Chimeric antigen receptor T (CAR-T) cell therapy represents a significant advancement in tumor immunotherapy, demonstrating notable efficacy in the treatment of hematological malignancies. Nevertheless, single-target CAR-T therapy encounters several challenges, including antigen escape, on-target off-tumor toxicity, and tumor heterogeneity. To address these limitations, dual-target CAR-T cell therapy has been developed. By recognizing two tumor antigens, dual-target CAR-T therapy broadens the antigen recognition spectrum of CAR-T cells and substantially mitigates the risk of antigen escape. Additionally, the incorporation of logic gate control design enhances its precision and minimizes on-target off-tumor toxicity. This review provides a comprehensive analysis of various dual-target CAR-T cell types, including sequential CAR-T cells, dual-signal CARs, tandem CARs, AND-gate CARs, and inhibitory CARs, with a focus on their applications and therapeutic efficacy in hematological malignancies. Furthermore, this review provides an in-depth examination of the unique advantages, current research progress, and challenges associated with dual-target CAR-T cell therapy.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"214 ","pages":"Article 104824"},"PeriodicalIF":5.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144556605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elucidating the mechanistic role of ovarian cancer biomarkers: Lessons learnt from affinity-proteomics","authors":"Anna Mary Steitz ,&nbsp;Silke Reinartz ,&nbsp;Vanessa M. Beutgen ,&nbsp;Rolf Müller ,&nbsp;Elke Pogge von Strandmann ,&nbsp;María Gómez-Serrano","doi":"10.1016/j.critrevonc.2025.104823","DOIUrl":"10.1016/j.critrevonc.2025.104823","url":null,"abstract":"<div><div>A salient feature of ovarian carcinoma (OC) is its unique tumor microenvironment (TME) enabling early onset of transcoelomic dissemination via the malignant ascites, with the omentum as a preferred site of tumor metastasis. These traits together with typical late diagnosis and high incidence of chemoresistance render OC the most lethal gynecological malignancy. Deciphering the mechanisms allowing tumor progression and metastasis represents an important aim in OC research. Also, there is a high medical need to identify biomarkers that could serve as diagnostic tools for detection of early and recurrent disease. Due to the easy access, one overarching goal is to define clinically relevant blood biomarkers reflecting the pro-tumorigenic features of the TME. For its part, the ascites better reflects the tumor secretome by holding large amounts of stromal, immune and tumor cells, as well as soluble secreted factors and extracellular vesicles, which justifies a more detailed analysis of the ascites proteome. Despite previous efforts based on mass-spectrometry analyses, biomarkers derived from these studies have so far not been integrated into clinical practice. Novel approaches applying affinity-based proteomics have more recently revolutionized biomarker research by providing systematic high-throughput analysis and highly sensitive detection. In the following, we discuss key findings in OC research applying these approaches to unravel intercellular crosstalk within the TME while identifying novel biomarkers. Understanding the origin, function and clinical impact of putative biomarkers is crucial, not only to depict the intercellular communication in the OC TME, but also to develop targeted therapies and improved diagnostic tools.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"214 ","pages":"Article 104823"},"PeriodicalIF":5.5,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144556183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regulatory mechanisms and therapeutic targeting of metastatic tumor dormancy in colorectal cancer: A comprehensive review","authors":"Yue Chen ,&nbsp;Jiaqi Zhang ,&nbsp;Jingying Sun ,&nbsp;Ann M. Bode ,&nbsp;Xiangjian Luo","doi":"10.1016/j.critrevonc.2025.104822","DOIUrl":"10.1016/j.critrevonc.2025.104822","url":null,"abstract":"<div><div>Metastatic tumor dormancy represents a key factor in CRC progression and treatment resistance. This systematic review aims to investigate the molecular regulatory mechanisms of metastatic tumor dormancy in CRC and critically evaluate therapeutic intervention strategies. Our analysis comprehensively examines the cellular and molecular biology of tumor dormancy, encompassing cell cycle regulation, key signal transduction pathways, and dynamic tumor cell-microenvironment interactions. Furthermore, we systematically evaluated therapeutic interventions targeting these mechanisms, such as targeted drugs, immunotherapy, microenvironmental therapy, and combinational therapies. This review provide new perspectives for understanding and targeting metastatic tumor dormancy in colorectal cancer, thereby establishing a rationale for enhancing patient prognosis and guiding the development of innovative anti-tumor strategies.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"213 ","pages":"Article 104822"},"PeriodicalIF":5.5,"publicationDate":"2025-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144546539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resistance mechanisms in anaplastic lymphoma kinase-positive lung cancer","authors":"Parnia Behinaein ,&nbsp;Shirish M. Gadgeel ,&nbsp;Ramandeep Rattan ,&nbsp;Jeffrey P. MacKeigan ,&nbsp;Amanda Pilling ,&nbsp;Fawzi Abu Rous ,&nbsp;Katie R. Martin ,&nbsp;Ikenna C. Okereke","doi":"10.1016/j.critrevonc.2025.104821","DOIUrl":"10.1016/j.critrevonc.2025.104821","url":null,"abstract":"<div><div>Non-small cell lung cancer has been discovered to have many unique molecular subsets that are associated with different phenotypic behaviors and overall prognoses. In particular, anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancers (NSCLCs) have distinctive presentations and disease courses. Patients with ALK NSCLC are typically younger, have significantly less smoking exposure, and often experience prolonged survival. When patients recur, drug-tolerant persister (DTP) cells may be implicated in disease recurrence. In this review we will discuss the phenomenon of DTP related to ALK NSCLC, possible mechanistic explanations and potential treatment strategies to eliminate DTPs.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"214 ","pages":"Article 104821"},"PeriodicalIF":5.5,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144519180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autophagy and oxidative stress in solid tumors: Mechanisms and therapeutic opportunities","authors":"María Carretero-Fernández ,&nbsp;Antonio José Cabrera-Serrano ,&nbsp;José Manuel Sánchez-Maldonado ,&nbsp;Lucía Ruiz-Durán ,&nbsp;Francisco Jiménez-Romera ,&nbsp;Francisco José García-Verdejo ,&nbsp;Carmen González-Olmedo ,&nbsp;Aina Cardús ,&nbsp;Leticia Díaz-Beltrán ,&nbsp;Juan Francisco Gutiérrez-Bautista ,&nbsp;Yolanda Benavente ,&nbsp;Fernando Gálvez-Montosa ,&nbsp;José Antonio López-López ,&nbsp;Paloma García-Martín ,&nbsp;Eva María Pérez ,&nbsp;Juan José Rodríguez-Sevilla ,&nbsp;Delphine Casabonne ,&nbsp;Pedro Sánchez-Rovira ,&nbsp;Fernando Jesús Reyes-Zurita ,&nbsp;Juan Sainz","doi":"10.1016/j.critrevonc.2025.104820","DOIUrl":"10.1016/j.critrevonc.2025.104820","url":null,"abstract":"<div><div>Cancer remains a leading cause of mortality worldwide, with solid tumors representing most cases. Autophagy and oxidative stress are two interconnected cellular mechanisms that influence tumor initiation, therapeutic response and disease progression. Autophagy plays a context-dependent role, functioning as a tumor suppressor by eliminating damaged organelles in early stages, while later supporting tumor survival under metabolic and therapeutic stress. Similarly, oxidative stress, characterized by an imbalance in reactive oxygen species (ROS), can drive tumorigenesis by promoting genomic instability and resistance to therapy but can also induce apoptosis in cancer cells. The crosstalk between autophagy and oxidative stress plays a pivotal role in shaping the tumor microenvironment, affecting immune evasion, drug resistance, and metabolic adaptation. Targeting these processes through pharmacological modulation presents both challenges and opportunities in cancer therapy. While autophagy inhibition can enhance chemotherapy efficacy by preventing tumor cell survival mechanisms, excessive oxidative stress induction may lead to cellular damage and systemic toxicity. This review explores the complex interplay between autophagy and oxidative stress in solid tumors, emphasizing their implications for cancer progression and treatment strategies. By understanding these mechanisms, novel therapeutic approaches, including combination therapies and precision medicine strategies, may be developed to improve patient outcomes.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"212 ","pages":"Article 104820"},"PeriodicalIF":5.5,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144523439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ferroptosis in tumor associated immune cells: A double-edged sword against tumors","authors":"Jiachun Hu ,&nbsp;Lei Cui ,&nbsp;Benxin Hou ,&nbsp;Xinyi Ding ,&nbsp;Haisheng Liu ,&nbsp;Weihong Sun ,&nbsp;Yanjun Mi ,&nbsp;Yibing Chen ,&nbsp;Zhengzhi Zou","doi":"10.1016/j.critrevonc.2025.104818","DOIUrl":"10.1016/j.critrevonc.2025.104818","url":null,"abstract":"<div><div>Ferroptosis is regulated cell death due to the accumulation of iron-dependent lipid peroxidation in cells, providing a potential new strategy for anti-tumor therapy. In recent years, more and more studies have begun to explore the interaction between ferroptosis and the tumor microenvironment (TME), especially the relationship between immune cells in the TME and ferroptosis, revealing the role of ferroptosis in tumor immunotherapy. This article summarizes the main metabolic pathways and regulatory mechanisms of ferroptosis, and focuses on the new role of ferroptosis in immune cells in the TME, which may provide new diagnostic, prognostic or therapeutic opportunities for the cooperation of immunotherapy and ferroptosis treatment.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"212 ","pages":"Article 104818"},"PeriodicalIF":5.5,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144510017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A new era for radium-223? Optimizing treatment by balancing efficacy and toxicity through combination therapies","authors":"Giovanni Farinea ,&nbsp;Luca Cozzone ,&nbsp;Simona Butticè ,&nbsp;Andrea Mogavero ,&nbsp;Rosario Francesco Di Stefano ,&nbsp;Tiziana Angusti ,&nbsp;Antonella Parente ,&nbsp;Marcello Tucci ,&nbsp;Consuelo Buttigliero","doi":"10.1016/j.critrevonc.2025.104819","DOIUrl":"10.1016/j.critrevonc.2025.104819","url":null,"abstract":"<div><div>The pronounced bone tropism of prostate cancer (PCa) has prompted the development of therapies that specifically act in areas of increased bone deposition and selectively exert anti-tumor effects in osteoblastic metastases. Radium-223 dichloride is a calcium-mimetic agent that targets bone lesions, disrupting the vicious circle between tumor cells and the bone microenvironment, and it has been shown to improve survival in metastatic castration-resistant prostate cancer (mCRPC) patients. Moreover, the combination of radium-223 with androgen receptor pathway inhibitors (ARPIs), despite showing promising antitumor activity, have also produced conflicting safety results, highlighting the importance of bone health in optimizing radium-223 use. The therapeutic landscape of PCa is rapidly evolving, with several other agents approved over the past fifteen years that have repeatedly reshaped the treatment algorithm since the introduction of radium-223. Furthermore, the capacity of radium-223 to induce DNA damage in tumor cells provides a strong rationale for potential synergy with PARP inhibitors and immunotherapeutic agents. This review refocuses attention on this radionuclide, providing an updated perspective to re-evaluate the role of radium-223 in the era of radioligands and precision medicine, along with a critical overview of promising future combinations for the treatment of PCa.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"214 ","pages":"Article 104819"},"PeriodicalIF":5.5,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144502093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unlock the code of MHC II-enabled Cancer immunotherapy","authors":"Jiaqi Liu ,&nbsp;Xueru Song ,&nbsp;Wenqi Guo ,&nbsp;Wanyi Liu ,&nbsp;Shaokang Xu ,&nbsp;Yan Yang ,&nbsp;Xiaoyuan Chu ,&nbsp;Zengjie Lei","doi":"10.1016/j.critrevonc.2025.104813","DOIUrl":"10.1016/j.critrevonc.2025.104813","url":null,"abstract":"<div><div>Major Histocompatibility Complex class II (MHC II) molecules present tumor antigens to CD4 + T cells, playing a pivotal role in initiating anti-cancer immunity. Recent discoveries of MHC II expression on atypical antigen-presenting cells (APCs) have spurred interest in targeting MHC II for immunotherapy. Emerging therapies seek to enhance MHC II expression in tumors, particularly immunologically “cold” tumors with limited T-cell infiltration, to amplify CD4 + T cell-mediated anti-tumor responses. Clinical advances include MHC II-guided personalized vaccines, immune checkpoint blockade (ICB), and combination strategies showing promising efficacy. This review delineates MHC II-mediated immunoregulatory networks across professional and atypical APCs, explores their potential as biomarkers and therapeutic targets, and discusses predictive models of MHC II-antigen interactions to advance precision oncology. By elucidating the complexity of MHC II-driven immune regulation, this work aims to optimize immunotherapy design, address tumor heterogeneity, and foster tailored therapeutic approaches for diverse cancer types.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"214 ","pages":"Article 104813"},"PeriodicalIF":5.5,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144365009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endocrine consequences of cranial irradiation in children: Mechanisms, impacts, and sex differences","authors":"Yumeng Wang ,&nbsp;Wenkai Yu ,&nbsp;Yiran Xu ,&nbsp;Changlian Zhu","doi":"10.1016/j.critrevonc.2025.104817","DOIUrl":"10.1016/j.critrevonc.2025.104817","url":null,"abstract":"<div><div>Cranial irradiation is a vital adjunctive therapy for pediatric brain tumors and acute lymphoblastic leukemia, significantly improving survival outcomes. However, it is often associated with complications, including neurodevelopmental disorders, endocrine dysfunctions, and obesity. This review explores the endocrine complications linked to cranial irradiation, focusing on its impact on the pituitary gland, hypothalamus, salivary glands, and thyroid gland. We discuss how radiation-induced hormonal imbalances contribute to growth restriction, obesity, and reproductive dysfunctions, with an emphasis on gender-specific differences in these outcomes. The underlying mechanisms likely involve the heightened radiation sensitivity in the hypothalamus and pituitary gland, leading to complex disruptions in hormonal regulation. Understanding these mechanisms is essential for developing targeted interventions to reduce long-term endocrine side effects and enhance quality of life for survivors.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"214 ","pages":"Article 104817"},"PeriodicalIF":5.5,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144478249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}